MedDocIQ — Full-Lifecycle Physician-Led Clinical Trial Documentation for Uzbekistan and Central Asia
Physician-Led | US-Based | Uzbekistan-first | Central Asia expansion
MedDocIQ provides full trial lifecycle clinical document support for clinical trials in Uzbekistan and Central Asia. From Protocol Feasibility Review through initial ICF Cultural Localization, amendments, safety updates, and close-out documentation — we stay with your trial as your dedicated documentation partner, not a one-off vendor.
Built by a team with direct clinical trial operations experience and native Central Asian linguistic expertise. Our physician-led workflow combines clinical review with native Russian and Uzbek linguists to deliver audit-friendly documentation with tracked changes, Study Glossary, Clinical Intent Verification Note (CIVN), and Localization Validation Certificate.
Our Services
Tier 1: Trial Startup Bundle — Feasibility to ICF Cultural Localization
The complete physician-led startup package: feasibility de-risk + ICF localization in one coordinated workflow. Includes Protocol Feasibility and Readiness Memo, SoA to ICF Alignment Map, Study Glossary + Term Decision Register, tracked-changes + clean copy (RU and/or UZ), and Clinical Intent Verification Note (CIVN). Your glossary and terminology decisions carry forward into every subsequent amendment and safety update — ensuring consistency across the entire trial lifecycle. Pricing: Custom.
Tier 2: Protocol Feasibility Only (Uzbekistan lens)
Physician-led review of your English draft protocol through a Uzbekistan-specific lens, identifying execution risks, ethics committee friction points, and patient-facing clarity gaps before a single word is localized. Includes risk memo, ICF-relevant risk flags, SoA to ICF Alignment Notes, Study Glossary starter, and optional sponsor handoff call. Pricing: Custom.
Tier 3: ICF Cultural Localization + Clinical Validation (RU/UZ) — $1,200
Native Uzbek and Russian linguists localize your ICF for patient-facing clarity, followed by physician clinical review to confirm intent and terminology consistency. Turnaround: 7 to 10 business days. Includes tracked-changes + clean copy, physician Clinical QC (GCP-aware), glossary alignment, and CIVN.
Tier 4: Second-Pass Clinical Validation (Existing RU/UZ)
Already have a RU/UZ ICF from another vendor? Our physician team reviews clinical intent, terminology consistency, and patient-facing clarity, returning a tracked correction set prepared to support ethics re-submission. Pricing: Custom.
Full Trial Lifecycle Document Support
MedDocIQ is not a one-off startup vendor. We provide ongoing documentation support throughout the entire trial lifecycle — ICF amendments, protocol amendment-driven ICF updates, safety-related consent revisions, regulatory correspondence, and close-out documentation. Because we maintain your Study Glossary and terminology decisions from day one, every subsequent document version maintains consistent clinical language and physician-validated accuracy.
Why MedDocIQ?
Full Trial Lifecycle Partner:
From feasibility through close-out — not just startup. We stay with your trial for every amendment, safety update, and regulatory submission.
Physician-Led Medical Accuracy Review:
Medical meaning reviewed by a physician to protect clinical intent and reduce avoidable rework during ethics/IRB review.
GCP-Aware Quality Control:
Structured QA checklist supports consistency, completeness, and terminology alignment appropriate for clinical trial documentation.
Native Russian + Uzbek Linguists:
Native linguists with English-source ICF focus.
Glossary and Terminology Consistency:
Master glossary ensures consistent medical language across all ICF sections and versions — enforced from initial ICF through every amendment.
On-the-Ground Familiarity:
Direct familiarity with the clinical research environment in Tashkent, including relationships with local investigators and clinical facilities.
Why Central Asia for Clinical Trials?
Central Asia represents a rapidly growing frontier for clinical trials. Uzbekistan has a population exceeding 36 million and the largest pharmaceutical market in Central Asia at over $2 billion, with 36%+ year-over-year growth. The region offers large treatment-naive patient populations, minimal trial competition, cost-effectiveness, and a modernizing regulatory environment.
Our Process
MedDocIQ follows a structured, physician-led methodology: (1) Protocol Feasibility Review through an Uzbekistan-specific lens, (2) ICF Cultural Localization by native RU/UZ linguists, (3) Physician Clinical Validation for intent and terminology, (4) Audit-friendly delivery with full artifact package. For ongoing trials, we maintain terminology governance across all amendments and safety updates using the established Study Glossary and Term Decision Register.
About MedDocIQ
MedDocIQ is a US-based, physician-led clinical trial documentation company. Built by a team with direct clinical trial operations experience and native Central Asian linguistic expertise, MedDocIQ specializes in full-lifecycle document support for clinical trials in Uzbekistan and Central Asia. The team combines physician clinical review, GCP-aware quality control, and native Russian and Uzbek linguists to deliver documentation that preserves clinical intent from first ICF through final close-out.
Coming Soon
Central Asia Expansion: Kazakhstan, Kyrgyzstan, and Tajikistan. Additional patient-facing document localization including recruitment materials, patient brochures, and participant diaries/questionnaires.
Navigate
Contact
Email:
contact@meddociq.com
LinkedIn:
linkedin.com/company/meddociq